These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 20053189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
    Weckermann D, Harzmann R.
    Eur Urol; 2004 Sep; 46(3):279-83; discussion 283-4. PubMed ID: 15306097
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M.
    Clin Ther; 2009 Sep; 31 Pt 2():2312-31. PubMed ID: 20110043
    [Abstract] [Full Text] [Related]

  • 13. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB, Campion M.
    Mol Urol; 2000 Sep; 4(3):275-7. PubMed ID: 11062384
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H.
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC.
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [Abstract] [Full Text] [Related]

  • 17. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE.
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [Abstract] [Full Text] [Related]

  • 18. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C.
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [Abstract] [Full Text] [Related]

  • 19. Utility of LHRH antagonists for advanced prostate cancer.
    Moul JW.
    Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
    [Abstract] [Full Text] [Related]

  • 20. The role of LHRH antagonists in the treatment of prostate cancer.
    Crawford ED, Hou AH.
    Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.